[
    "Q ID NO. 46 and the light chain sequence has at least 93% sequence identity with SEQ ID NO. 47; the heavy chain sequence has at least 94% sequence identity with SEQ ID NO. 46 and the light chain sequence has at least 94% sequence identity with SEQ ID NO. 47; the heavy chain sequence has at least 95% sequence identity to SEQ ID NO. 46 and the light chain sequence has at least 95% sequence identity to SEQ ID NO. 47; the heavy chain sequence has at least 96% sequence identity with SEQ ID NO. 46 and the light chain sequence has at least 96% sequence identity with SEQ ID NO. 47; the heavy chain sequence has at least 97% sequence identity to SEQ ID NO. 46 and the light chain sequence has at least 97% sequence identity to SEQ ID NO. 47; the heavy chain sequence has at least 98% sequence identity with SEQ ID NO. 46 and the light chain sequence has at least 98% sequence identity with SEQ ID NO. 47; the heavy chain sequence has at least 99% sequence identity to SEQ ID NO. 46 and the light chain sequence has at least 99% sequence identity to SEQ ID NO. 47; or the heavy chain sequence comprises SEQ ID NO 46 and the light chain sequence comprises SEQ ID NO 47.</p>In another embodiment, the antibody binds human, mouse, or cynomolgus PD-L1. In a particular aspect, the antibody is capable of blocking the interaction between human, mouse or cynomolgus PD-L1 and the corresponding human, mouse or cynomolgus PD-1 receptor.</p>In another embodiment, the antibody is at 5x10<sup>-9</sup>M or lower KD, preferably at 2x10<sup>-9</sup>M or lower KD, even more preferably at 1x10<sup>-9</sup>M or lower KD binds to human PD-L1.</p>In another embodiment, the disclosure relates to an anti-PD-L1 antibody or antigen-binding fragment thereof that binds to a functional epitope comprising residues Y56 and D61 of human PD-L1.</p>In a specific aspect, the functional epitope further comprises E58, E60, Q66, R113, and M115 of human PD-L1.</p>In a more specific aspect, the antibody binds to a conformational epitope comprising residues 54-66 and 112-122 of human PD-L1.</p>In certain embodiments, the disclosure relates to an anti-PD-L1 antibody or antigen-binding fragment thereof that cross-competes for binding to PD-L1 with an antibody of the disclosure described herein.</p>In certain embodiments, the present disclosure includes proteins and polypeptides comprising any of the above anti-PD-L1 antibodies, in combination with at least one pharmaceutically acceptable carrier.</p>In certain embodiments, the disclosure includes an isolated nucleic acid encoding a polypeptide, or a light chain or heavy chain variable region sequence, of an anti-PD-L1 antibody or antigen-binding fragment thereof described herein. In certain embodiments, the present disclosure provides an isolated nucleic acid encoding a light chain or heavy chain variable region sequence of an anti-PD-L1 antibody, wherein:</p>(a) the heavy chain comprises HVR-H1, HVR-H2, and HVR-H3 sequences that have at least 80% sequence identity to SYIMM (SEQ ID NO:35), SIYPSGGITFYADTVKG (SEQ ID NO:36), and IKLGTVTTVDY (SEQ ID NO:37), respec"
]